[go: up one dir, main page]

WO2005081716A3 - DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV) - Google Patents

DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV) Download PDF

Info

Publication number
WO2005081716A3
WO2005081716A3 PCT/US2004/039579 US2004039579W WO2005081716A3 WO 2005081716 A3 WO2005081716 A3 WO 2005081716A3 US 2004039579 W US2004039579 W US 2004039579W WO 2005081716 A3 WO2005081716 A3 WO 2005081716A3
Authority
WO
WIPO (PCT)
Prior art keywords
sars
cov
responses
polypeptides
acute respiratory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/039579
Other languages
French (fr)
Other versions
WO2005081716A2 (en
Inventor
Tzyy-Choou Wu
Chien-Fu Hung
Tae Woo Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of WO2005081716A2 publication Critical patent/WO2005081716A2/en
Anticipated expiration legal-status Critical
Publication of WO2005081716A3 publication Critical patent/WO2005081716A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention provides compositions and methods for inducing and enhancing immune responses, particularly antigen-specific CD8+ T cell mediated responses, against antigens of the SARS coronavirus. These antigens include epitopes of the Membrane (M), Envelope (E), Spike (S) and Nucleocapsid (N) proteins of the virus. Such responses are induced using DNA constructs as an immunogens or vaccines, which encode chimeric polypeptides comprising endoplasmic reticulum chaperone polypeptides, such as human calreticulin (CRT) and an antigenic peptide or polypeptide. In particular, the invention provides compositions and methods for enhancing immune responses induced by polypeptides made in vivo by administered nucleic acid, such as naked DNA or expression vectors, encoding the chimeric molecules. Such enhanced immunity, whether T cell mediated or antibody-mediated protects an infected subject from infection or spread of the SARS CoV in vivo.
PCT/US2004/039579 2003-11-24 2004-11-24 DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV) Ceased WO2005081716A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52447903P 2003-11-24 2003-11-24
US60/524,479 2003-11-24

Publications (2)

Publication Number Publication Date
WO2005081716A2 WO2005081716A2 (en) 2005-09-09
WO2005081716A3 true WO2005081716A3 (en) 2009-04-02

Family

ID=34910678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/039579 Ceased WO2005081716A2 (en) 2003-11-24 2004-11-24 DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)

Country Status (1)

Country Link
WO (1) WO2005081716A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US7342002B2 (en) 2000-08-03 2008-03-11 The Johns Hopkins University Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen
EP1363660A4 (en) 2001-02-01 2006-06-21 Univ Johns Hopkins "SUPERIOR MOLECULAR VACCINE BASED ON SELF-REPLICATING RNA, SUICIDE DNA OR NAKED DNA VECTOR, FOR CONNECTING ANTIGEN WITH POLYPEPTIDE TO PROMOTE ANTIGEN PRESENTATION"
WO2004098526A2 (en) 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
CA2594040A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
WO2006095180A2 (en) * 2005-03-10 2006-09-14 Ultra Biotech Limited Humananized monoclonal antibodies against sars - associated coronavirus and treatment of patients with sars
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
CN101915848B (en) * 2010-07-06 2013-09-25 中国医学科学院病原生物学研究所 Application of RBD protein in preparation of auxiliary diagnostic agent for SARS patients
US9884895B2 (en) 2014-03-20 2018-02-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
WO2019051127A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
CN111836639A (en) * 2018-01-26 2020-10-27 河谷细胞有限公司 Compositions and methods for combination cancer vaccines and immune adjuvant therapy
CN111196857B (en) * 2020-02-05 2023-07-21 杭州贤至生物科技有限公司 Novel coronavirus multi-epitope recombinant antigen and preparation method thereof
WO2021195411A1 (en) * 2020-03-25 2021-09-30 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
US20230210978A1 (en) * 2020-04-02 2023-07-06 Francois Binette A universal adoptive immunotherapy approach to treat covid-19 and future emerging infectious diseases
CN111440229B (en) * 2020-04-13 2021-08-03 中国人民解放军军事科学院军事医学研究院 Novel coronavirus T cell epitopes and their applications
JP2023522278A (en) * 2020-04-23 2023-05-29 エフ． ホフマン－ラ ロシュ アーゲー Corona nucleocapsid antigen for use in antibody-immunoassays
WO2021236415A1 (en) * 2020-05-18 2021-11-25 The Regents Of The University Of California Safe potent single vector platform vaccine against covid-19
EP4162060A4 (en) * 2020-06-05 2024-09-11 EpicentRx, Inc. MONO- AND MULTIVALENT SARS-CoV-2 ADENOVIRAL VECTOR VACCINES AND SARS-CoV-2 IMMUNE GLOBULIN AND METHODS OF USE
CN111978376B (en) * 2020-06-15 2022-02-18 江苏安泰生物技术有限公司 Pharmaceutical composition for preventing and/or treating coronavirus infection, and preparation method and application thereof
WO2022026921A1 (en) * 2020-07-30 2022-02-03 Repertoire Immune Medicines, Inc. Identification and use of t cell epitopes in designing diagnostic and therapeutic approaches for covid-19
TWI839716B (en) * 2021-05-18 2024-04-21 法信諾生醫股份有限公司 Peptide vaccine for virus infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012281A2 (en) * 2000-08-03 2002-02-14 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012281A2 (en) * 2000-08-03 2002-02-14 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARRA M. ET AL.: "The Genome sequence of the SARS-associated coronavirus", SCIENCE., vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1399 - 1404, XP002288939, DOI: doi:10.1126/science.1085953 *
RUAN Y. ET AL.: "Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection", LANCET, vol. 361, no. 9371, 24 May 2003 (2003-05-24), pages 1779 - 1785, XP004783474, DOI: doi:10.1016/S0140-6736(03)13414-9 *

Also Published As

Publication number Publication date
WO2005081716A2 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
WO2005081716A3 (en) DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
Hashem et al. A highly immunogenic, protective, and safe adenovirus-based vaccine expressing Middle East respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model
WO2002080851A3 (en) Chimeric vaccines
WO2002012281A3 (en) Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
Fan et al. Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
IL189313A0 (en) Virus-like particles as vaccines for paramyxovirus
MX342639B (en) High titer recombinant influenza viruses for vaccines and gene therapy.
ES2775278T3 (en) Composition consisting of an antigen linked to a ligand of the TNF superfamily
DK1002110T3 (en) Immune response to HPV antigens induced by compositions comprising an HPV antigen and a stress protein or expression vector capable of expressing these proteins
EA200700849A1 (en) PRIMARY / BOOSTER ANTI-MALARY VACCINE
WO2010039224A3 (en) Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
MX2019003682A (en) Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same.
WO2004050856A3 (en) Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
WO2021178623A1 (en) Immunogenic compositions against severe acute respiratory syndrome coronavirus 2
Olivera et al. Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice
Guo et al. A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
Laotee et al. CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2
Nanishi et al. Alum: CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity
WO2006071896A3 (en) Epitope-based sars vaccine
ATE450545T1 (en) LAWSONIA INTRACELLULARIS SUBUNIT VACCINE
AU6683400A (en) Vaccine against lentiviral infections, such as the feline immune deficiency virus of the cat
Yang et al. Immune responses to T-cell epitopes of SARS CoV-N protein are enhanced by N immunization with a chimera of lysosome-associated membrane protein
CN115515628A (en) Mumps and measles virus immunogens and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase